Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Nelson Dusetti

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-6161-8483; OpenAlex author ID A5002621255. Sources: OpenAlex.

Their work

Papers
93 (first author 5, last author 15)
Trials
0
Grants
0
Labs led
1
Collaborators
248
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: none · 2015: 5 papers · 2016: 3 papers · 2017: 5 papers · 2018: 4 papers · 2019: 5 papers · 2020: 6 papers · 2021: 9 papers · 2022: 11 papers · 2023: 7 papers · 2024: 10 papers · 2025: 11 papers · 2026: 15 papers

Papers 50 of 93

  1. Decoding the Integrated Stress Response of Pancreatic Cancer: Identifying a Serine-dependent Tumor Subset Under Metabolic Relationships With CAFs. Co-author DOI 10.1002/advs.202515740↗
  2. When defense turns dangerous: The dual nature of senescence in pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.critrevonc.2026.105328↗
  3. Targeted therapeutic strategies in rare subtypes of pancreatic cancer: Histology, molecular profiles, and emerging opportunities. First author DOI 10.1016/j.ctrv.2026.103123↗
  4. Toward precision chemotherapy in pancreatic ductal adenocarcinoma: molecular, transcriptomic and clinical determinants. Co-author DOI 10.1016/j.dld.2026.02.020↗
  5. Stage-resolved gene drivers of pancreatic ductal adenocarcinoma progression and therapeutic vulnerabilities. Co-author DOI 10.1016/j.isci.2026.115164↗
  6. Pathway-driven therapeutic stratification in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2026.102920↗
  7. Single-cell transcriptomic profiling of patient-derived pancreatic ductal adenocarcinoma primary cell cultures. Co-author DOI 10.1038/s41597-026-07380-3↗
  8. A comprehensive proteomic dataset of secretomes from primary pancreatic cancer cell cultures. Co-author DOI 10.1038/s41597-026-07902-z↗
  9. ATM Deficiency Induces TGFβ-Mediated Stromal Programming in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-26-0138↗
  10. SG33, a Vaccine Strain of Myxoma Virus with Oncolytic Potential, Exploits Macropinocytosis and Clathrin-Mediated Endocytosis for Entry into Pancreatic Cancer C… Co-author DOI 10.1177/10430342261441043↗
  11. Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study. Co-author DOI 10.1200/jco-25-02508↗
  12. Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer. Co-author DOI 10.1200/jco-26-00327↗
  13. A genome-wide CRISPR-Cas9 screen identifies TGN46 as a host determinant for H-1PV susceptibility in pancreatic adenocarcinoma Co-author DOI 10.64898/2026.03.06.710102↗
  14. Co-translational O-glycosylation driven by GALNTs spatial reprogramming fosters pancreatic cancer growth Co-author DOI 10.64898/2026.09.04.749345↗
  15. Transcriptomic FOLFIRINOX sensitivity signatures stratify overall survival and reveal directional reclassification after neoadjuvant FOLFIRINOX in borderline r… Co-author DOI 10.64898/2026.09.07.749857↗
  16. Redefining phenotypic intratumor heterogeneity of pancreatic ductal adenocarcinoma: a bottom-up approach. Co-author DOI 10.1002/path.6398↗
  17. Toward Precision Chemotherapy for Pancreatic Cancer Guided by Transcriptomic Signatures. Last author DOI 10.1002/ueg2.70124↗
  18. Reply to the Letter to the Editor 'AI-assisted personalized adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma' by Y. Shimazu. Last author DOI 10.1016/j.annonc.2024.09.016↗
  19. Medical management of pancreatic cancer: from personalization to broadening treatment strategies. Co-author DOI 10.1016/j.ctrv.2025.102973↗
  20. KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2025.102421↗
  21. Understanding the heterogeneity of pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.tranon.2025.102479↗
  22. A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance. Co-author DOI 10.1073/pnas.2523039122↗
  23. The PancreasView gemcitabine transcriptomic signature predicts response to gemcitabine in patients with resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/oncolo/oyaf083↗
  24. E-Cadherin Is a Structuring Component of Invadopodia in Pancreatic Cancer. Co-author DOI 10.1111/jcmm.70608↗
  25. The T-Box Transcription Factors TBX2 and TBX3 Are Molecular Targets of Piroctone Olamine in the Treatment of Pancreatic Cancer. Co-author DOI 10.1111/jcmm.70736↗
  26. TP53 missense-specific transcriptional plasticity drives resistance against cell cycle inhibitors in pancreatic cancer. Co-author DOI 10.1126/sciadv.adu2339↗
  27. High-resolution and quantitative spatial analysis reveal intra-ductal phenotypic and functional diversification in pancreatic cancer. Co-author DOI 10.1002/path.6212↗
  28. Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.annonc.2024.06.010↗
  29. Predictive genomic and transcriptomic analysis on endoscopic ultrasound-guided fine needle aspiration materials from primary pancreatic adenocarcinoma: a prosp… Co-author DOI 10.1016/j.ebiom.2024.105373↗
  30. Minute virus of mice shows oncolytic activity against pancreatic cancer cells exhibiting a mesenchymal phenotype. Co-author DOI 10.1016/j.omton.2024.200780↗
  31. Cytidine deaminase-dependent mitochondrial biogenesis as a potential vulnerability in pancreatic cancer cells. Co-author DOI 10.1038/s42003-024-06760-y↗
  32. Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs. Co-author DOI 10.1158/0008-5472.can-22-3219↗
  33. EZH2 deletion does not affect acinar regeneration but restricts progression to pancreatic cancer in mice. Co-author DOI 10.1172/jci.insight.173746↗
  34. Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CC… Co-author DOI 10.1200/jco.22.02668↗
  35. Development of transcriptomic tools for predicting the response to individual drug of the mFOLFIRINOX regimen in patients with metastatic pancreatic cancer. Co-author DOI 10.3389/fonc.2024.1437200↗
  36. The xenobiotic transporter ABCC4/MRP4 promotes epithelial mesenchymal transition in pancreatic cancer. Co-author DOI 10.3389/fphar.2024.1432851↗
  37. Priming therapy by targeting enhancer-initiated pathways in patient-derived pancreatic cancer cells. Co-author DOI 10.1016/j.ebiom.2023.104602↗
  38. Pancreatic ductal adenocarcinoma ubiquitination profiling reveals specific prognostic and theranostic markers. Co-author DOI 10.1016/j.ebiom.2023.104634↗
  39. Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression in vivo. Co-author DOI 10.1016/j.isci.2023.106899↗
  40. Pacpaint: a histology-based deep learning model uncovers the extensive intratumor molecular heterogeneity of pancreatic adenocarcinoma. Co-author DOI 10.1038/s41467-023-39026-y↗
  41. A Transcriptomic-Based Tool to Predict Gemcitabine Sensitivity in Advanced Pancreatic Adenocarcinoma. Last author DOI 10.1053/j.gastro.2022.11.035↗
  42. SK2 channels set a signalling hub bolstering CAF-triggered tumourigenic processes in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2021-326610↗
  43. [The mRNA vaccine for the treatment of pancreatic cancer is here to stay]. Co-author PMID 37582144↗
  44. Limitation and challenges in using pancreatic cancer-derived organoids as a preclinical tool. Co-author DOI 10.1002/cac2.12335↗
  45. Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity. Co-author DOI 10.1002/cac2.12365↗
  46. Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict adjuvant chemosensitivity in pancreatic c… Last author DOI 10.1016/j.tranon.2021.101315↗
  47. Iron-Sensitive Prodrugs That Trigger Active Ferroptosis in Drug-Tolerant Pancreatic Cancer Cells. Co-author DOI 10.1021/jacs.2c03973↗
  48. Sympathetic axonal sprouting induces changes in macrophage populations and protects against pancreatic cancer. Co-author DOI 10.1038/s41467-022-29659-w↗
  49. Multi-omics data integration and modeling unravels new mechanisms for pancreatic cancer and improves prognostic prediction. Co-author DOI 10.1038/s41698-022-00299-z↗
  50. PACpAInt: a deep learning approach to identify molecular subtypes of pancreatic adenocarcinoma on histology slides Co-author DOI 10.1101/2022.01.04.474951↗

Closest collaborators

The 25 strongest of 248 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Juan Iovanna · 71 shared papers, 2011–2026 · strength 10.48
  2. Nicolas Alejandro Fraunhoffer · 27 shared papers, 2020–2026 · strength 5.60
  3. Rémy Nicolle · 26 shared papers, 2017–2026 · strength 3.52
  4. Odile Gayet · 27 shared papers, 2015–2026 · strength 2.93
  5. Brice Chanez · 12 shared papers, 2022–2026 · strength 2.60
  6. Julie Roques · 18 shared papers, 2016–2026 · strength 2.44
  7. Jerome F. Cros · 15 shared papers, 2019–2026 · strength 2.20
  8. Pascal R. Hammel · 12 shared papers, 2021–2026 · strength 2.14
  9. Cindy Neuzillet · 9 shared papers, 2021–2026 · strength 1.81
  10. Raul A. Urrutia · 12 shared papers, 2016–2025 · strength 1.67
  11. Jean‐Baptiste Bachet · 11 shared papers, 2016–2026 · strength 1.61
  12. Gwen Alyce Lomberk · 12 shared papers, 2016–2025 · strength 1.39
  13. Louis Buscail · 7 shared papers, 2020–2026 · strength 1.38
  14. Analía Meilerman Abuelafia · 8 shared papers, 2020–2026 · strength 1.37
  15. Daniel Grasso · 5 shared papers, 2023–2026 · strength 1.31
  16. Pierre Cordelier · 6 shared papers, 2022–2026 · strength 1.30
  17. Eduardo Chuluyán · 7 shared papers, 2020–2026 · strength 1.20
  18. Abdessamad El Kaoutari · 9 shared papers, 2020–2024 · strength 1.19
  19. Philippe Soubeyran · 6 shared papers, 2019–2026 · strength 1.18
  20. Anthony Turpin · 6 shared papers, 2022–2026 · strength 1.12
  21. Vinciane Rebours · 7 shared papers, 2022–2026 · strength 1.08
  22. Louis de Mestier · 6 shared papers, 2022–2026 · strength 1.03
  23. Richard Tomasini · 9 shared papers, 2013–2026 · strength 0.96
  24. Jonathan Garnier · 5 shared papers, 2016–2026 · strength 0.78
  25. Naïma Hanoun · 4 shared papers, 2022–2026 · strength 0.77

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.